Scarica l'app Stockscreener
122.00
8.07%
9.11
Pre-mercato:
118.00
-4.00
-3.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$112.89
Aprire:
$112.89
Volume 24 ore:
7.25M
Relative Volume:
1.96
Capitalizzazione di mercato:
$25.79B
Reddito:
$381.03M
Utile/perdita netta:
$-1.01B
Rapporto P/E:
-20.50
EPS:
-5.95
Flusso di cassa netto:
$-789.25M
1 W Prestazione:
+9.31%
1M Prestazione:
+24.26%
6M Prestazione:
+53.27%
1 anno Prestazione:
+64.66%
Intervallo 1D:
$112.48
$122.03
Intervallo di 1 settimana:
$106.54
$122.03
Portata 52W:
$60.40
$122.03
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Confronta INSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
122.00 | 23.86B | 381.03M | -1.01B | -789.25M | -5.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Insmed stock rating downgraded to Equalweight by Morgan Stanley - Investing.com Canada
Insmed (INSM) Surges 8.07% as Bullish Candlesticks and MACD Golden Cross Signal 65% Outperformance Probability - AInvest
Insmed Surges 8.07% on FDA Approval as $870M Trading Volume Hits Top 500 Daily Rank - AInvest
US FDA approves Insmed's drug as first treatment for a chronic lung disease - Reuters
Wells Fargo Raises Price Target for INSM to $140, Maintains Over - GuruFocus
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease - AOL.com
FDA Approves Insmed’s Brensocatib as First Therapy for Non-Cystic Fibrosis Bronchiectasis - geneonline.com
Insmed gains US approval of lung disease drug forecast to be blockbuster - BioPharma Dive
Brinsupri dose choice means bronchiectasis upside, Insmed says - BioWorld MedTech
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval - Investor's Business Daily
Jefferies raises Insmed stock price target to $148 on Brinsupri approval - Investing.com Canada
Insmed scores FDA clearance for Brinsupri in NCFB - BioWorld MedTech
Why Is Insmed Stock Trading Higher TodayInsmed (NASDAQ:INSM) - Benzinga
Insmed's Brinsupri: A Blockbuster Launch in a Neglected Market - AInvest
Insmed stock rises on FDA nod for lung disorder drug Brinsupri - Seeking Alpha
Insmed stock surges after FDA approves first NCFB treatment By Investing.com - Investing.com Canada
Insmed's FDA Approval of Brinsupri: A Strategic Win in the Orphan Drug Market and Its Implications for Shareholder Value - AInvest
US FDA approves Insmed's lung disease drug - Reuters
Insmed Drug Wins First US Approval for Debilitating Lung Disease - Bloomberg
FDA Makes History: First-Ever Treatment for 500,000 Non-Cystic Fibrosis Bronchiectasis Patients Gets Approval - Stock Titan
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease - Stocktwits
Analysts Bullish on Insmed and Ligand Pharma: Strong Buy Ratings and High Price Targets - AInvest
Insmed's 3.28% Two-Day Rally Fueled by Strong Candlestick Momentum and Bullish Moving Averages - AInvest
Insmed Surges 3.05% on 28.6% Japan Revenue Spike as $370M Volume Ranks 271st in Market Activity - AInvest
Insmed Hovers Near 110 Resistance As Technicals Signal Consolidation Risk - AInvest
Insmed stock hits 52-week high at 113.17 USD By Investing.com - Investing.com Nigeria
Insmed stock hits 52-week high at 113.17 USD - Investing.com
Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock - Yahoo Finance
Liquidia: Uncertainty Has Always Been A Buying Opportunity (LQDA) - Seeking Alpha
Strategic Implications of Insmed's Lock-Up Expiry and $650M Equity Raise on Shareholder Value and Market Position - AInvest
Insmed's Post-Lock-Up RSU Liquidity and Market Implications - AInvest
Will Insmed Incorporated bounce back from current support3-Year Equity Summary With Setup Insights - Newser
Insmed Incorporated (NASDAQ:INSM) Q2 2025 Earnings Call Transcript - Insider Monkey
Real time scanner hits for Insmed Incorporated explainedBollinger Band Squeeze and Expansion Analysis - Newser
H.C. Wainwright Maintains Buy Rating on Insmed with $120 Price Target - AInvest
Insmed's $350M Trade Ranks 273rd as High-Volume Strategy Generates 166% Alpha - AInvest
Insmed's Q2 net loss reaches $322M, but shares surge 68% amidst revenue guidance and Russell index inclusion. - AInvest
Insmed (INSM) Reports Increased Losses But Reiterates 2025 Revenue Guidance - Yahoo Finance
Insmed stock price target raised to $120 from $108 at RBC Capital - Investing.com Australia
UBS Adjusts Price Target on Insmed to $133 From $124, Maintains Buy Rating - MarketScreener
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $111.26 to $135 - 富途牛牛
RBC Raises Price Target on Insmed to $120 From $108, Keeps Outperform Rating - MarketScreener
Insmed price target raised to $133 from $124 at UBS - TipRanks
Insmed: Q2 Earnings Snapshot - Connecticut Post
Insmed Reports Q2 Earnings with 19% ARIKAYCE Revenue Growth and Positive TPIP Study Results - AInvest
Insmed Inc (INSM) Q2 2025 Earnings Call Highlights: Strong Finan - GuruFocus
Insmed Reports Strong Growth and Strategic Advances - TipRanks
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed Sets $405M-$425M ARIKAYCE Revenue Target as Brensocatib Launch Approaches and Pipeline Advances - AInvest
Insmed's Q2 2025: Key Contradictions in Bronchiectasis Strategy, Pricing, and Market Access - AInvest
Insmed stock price target raised to $129 by Jefferies ahead of PDUFA - Investing.com Australia
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.59%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):